Teva Pharmaceutical Industries Limited (VIE:TEVA)

Revenue by Product

Financials in millions ILA. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Generics, Innovative Medicines and Biopharmaceuticals	61.24B
Generics, Innovative Medicines and Biopharmaceuticals Growth	4.79%

Revenue by Geography

Financials in millions ILA. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
United States	29.74B
United States Growth	-0.74%
Europe	18.89B
Europe Growth	5.89%
International	9.12B
International Growth	26.26%
Global	3.49B
Global Growth	2.32%